NCT06807281 - A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema | Biotech Hunter

Enrollment

500

Participants

Timeline

Start Date

December 2, 2025

Primary Completion Date

February 22, 2032

Study Completion Date

February 22, 2032

Conditions

Atopic Dermatitis

Interventions

DRUG

Abrocitinib

Abrocitinib administered as liquid oral suspension.

Trial Locations (7)

Tribe Clinical Research, LLC, Greenville

Solutions Through Advanced Research, Jacksonville

Miami Dermatology and Laser Research, Miami

Cahaba Dermatology & Skin Health Center, Birmingham

Centricity Research Columbus Ohio Multispecialty, Columbus

Dawes Fretzin Clinical Research Group, LLC, Indianapolis

Arkansas Research Trials, North Little Rock